- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Marc Gitzinger, CEO BioVersys: «Unsere Investorenbasis ist sehr ausgewogen» | 4 | schweizeraktien.net | ||
| 19.02. | BioVersys: Phase-2a-Studie zur Tuberkulose-Behandlung zeigt vielversprechende Ergebnisse | 3 | Investing.com Deutsch | ||
| 19.02. | BioVersys phase 2a tuberculosis treatment shows promise in trial | 1 | Investing.com | ||
| 19.02. | Bioversys publiziert Tuberkulose-Daten in renommierten Fachjournal | 3 | cash | ||
| 19.02. | BioVersys AG: BioVersys and partners' phase 2a tuberculosis trial results published in New England Journal of Medicine | 477 | EQS Group (EN) | BioVersys AG
/ Key word(s): Scientific publication
BioVersys and partners' phase 2a tuberculosis trial results published in New England Journal of Medicine 19.02.2026 / 07:17... ► Artikel lesen | |
| BIOVERSYS Aktie jetzt für 0€ handeln | |||||
| 10.02. | BioVersys - Poised to unlock value in critical AMR | 334 | Edison Investment Research | BioVersys is focused on developing novel drugs to address antimicrobial resistance (AMR). Lead asset BV100 is targeting carbapenem-resistant Acinetobacter baumannii (CRAB) infections, a significant... ► Artikel lesen | |
| 09.01. | BioVersys - Targeting resistant and threatening indications | 501 | Edison Investment Research | BioVersys (BIOV) is a Swiss clinical-stage biopharmaceutical company developing novel anti-infectives to address antimicrobial resistance (AMR). Lead asset BV100 targets carbapenem-resistant Acinetobacter... ► Artikel lesen | |
| 11.12.25 | BioVersys initiates phase 3 trial for BV100 antibiotic candidate | 4 | Investing.com | ||
| 11.12.25 | BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update | 220 | GlobeNewswire (Europe) | Ad hoc announcement pursuant to Art. 53LR BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission... ► Artikel lesen | |
| 11.12.25 | Adhoc: BioVersys AG: BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update | 1.717 | EQS Group (EN) | BioVersys AG / Key word(s): Study
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update 11-Dec-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to... ► Artikel lesen | |
| 10.11.25 | BioVersys BV100 Phase 2b to be Conducted Via Wellcome Funded Trial Network | 3 | GlobeNewswire (USA) | ||
| 10.11.25 | Adhoc: BioVersys AG: BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network | 1.157 | EQS Group (EN) | BioVersys AG / Key word(s): Study/Funds
BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network 10-Nov-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant... ► Artikel lesen | |
| 06.11.25 | Adhoc: BioVersys AG: Bioversys announces first subjects dosed in Phase 1 clinical trial of BV100 in China | 1.674 | EQS Group (EN) | BioVersys AG / Key word(s): Study
Bioversys announces first subjects dosed in Phase 1 clinical trial of BV100 in China06-Nov-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 05.11.25 | BioVersys AG: Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york | 409 | EQS Group (EN) | BioVersys AG
/ Key word(s): Conference
Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york 05.11.2025 / 07:00 CET/CEST
Basel, Switzerland. November... ► Artikel lesen | |
| 03.11.25 | BioVersys AG: Bioversys announces appointment of anti-infective expert Dr. Daniel Ritz as Chief Scientific Officer and retirement of Dr. Sergio Lociuro | 363 | EQS Group (EN) | BioVersys AG
/ Key word(s): Personnel
Bioversys announces appointment of anti-infective expert Dr. Daniel Ritz as Chief Scientific Officer and retirement of Dr. Sergio Lociuro... ► Artikel lesen | |
| 10.09.25 | Adhoc: BioVersys AG: Bioversys reports corporate highlights and key financials for the first half 2025 | 2.481 | EQS Group (EN) | BioVersys AG / Key word(s): Half Year Results
Bioversys reports corporate highlights and key financials for the first half 2025 10-Sep-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 29.08.25 | BioVersys AG: Bioversys To announce its FIrst half 2025 financial results, Provide a business update And Host a Conference call | 494 | EQS Group (EN) | BioVersys AG
/ Key word(s): Half Year Results
Bioversys To announce its FIrst half 2025 financial results, Provide a business update And Host a Conference call 29.08.2025 / 07:00... ► Artikel lesen | |
| 27.08.25 | Adhoc: BioVersys AG: BioVersys receives EMA Orphan Designation for the combination of alpibectir and ethionamide for the treatment of tuberculosis | 1.092 | EQS Group (EN) | BioVersys AG / Key word(s): Regulatory Admission
BioVersys receives EMA Orphan Designation for the combination of alpibectir and ethionamide for the treatment of tuberculosis 27-Aug-2025... ► Artikel lesen | |
| 02.07.25 | Adhoc: BioVersys AG: BioVersys And Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate | 1.982 | EQS Group (EN) | BioVersys AG / Key word(s): Agreement/Partnership
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL... ► Artikel lesen | |
| 30.06.25 | Adhoc: Bioversys AG: Bioversys Announces Results From Its Annual General Meeting Of Shareholders | 879 | EQS Group (EN) | BioVersys AG / Key word(s): AGMEGM
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS 30-Jun-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,880 | +0,38 % | Evotec Aktie: Kann man "diesem Braten wirklich trauen"? | © Foto: Julia Koblitz auf Unsplash (Symbolbild)Neue Aufträge, ein Sparprogramm und frische Analystenkommentare. Die Evotec-Aktie sendet wieder Lebenszeichen. Doch wer die Geschichte dieses Hamburger... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,386 | -1,28 % | BioNxt Solutions Inc.: BioNxt Announces Closing of Shares for Debt Settlement | VANCOUVER, BC / ACCESS Newswire / February 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that, further to its news release dated... ► Artikel lesen | |
| MAINZ BIOMED | 0,748 | +2,78 % | Mainz BioMed NV: Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples | ||
| VIVORYON THERAPEUTICS | 1,444 | +0,56 % | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
Halle (Saale) / Munich, Germany, January 7, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon)... ► Artikel lesen | |
| KUROS BIOSCIENCES | 30,000 | +1,28 % | Kuros Biosciences AG: Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences | Kuros Biosciences to provide investor updateat Octavian and Baader Bank Conferences
Schlieren (Zürich), Switzerland, January 13, 2026 - Kuros Biosciences ("Kuros" or the "Company") a leader in innovative... ► Artikel lesen | |
| ABIVAX | 101,80 | -0,97 % | 2 Reasons Abivax Stock Could 10X by 2036 | ||
| BASILEA | 60,60 | +0,33 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea erhält weitere USD 6 Mio. von BARDA zur Weiterentwicklung des neuartigen Antibiotikums Ceftibuten-Ledaborbactam | Ad hoc-Mitteilung gemäss Art. 53 KR
Allschwil, 25. Februar 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem... ► Artikel lesen | |
| IDORSIA | 4,265 | -0,47 % | Idorsia verdoppelt 2025 Umsatz und reduziert den Verlust | Allschwil - Das Biotechunternehmen Idorsia schaut auf ein bewegtes 2025 zurück. Dabei ist es dem Unternehmen gelungen, weiter zu wachsen. Der Umsatz kletterte 2025 auf 221 Millionen Franken von 113... ► Artikel lesen | |
| IMMATICS | 8,800 | +1,09 % | Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress | IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor... ► Artikel lesen | |
| MINDMAZE THERAPEUTICS | 0,762 | 0,00 % | MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics | Relief Therapeutics Holding SA
/ Key word(s): Miscellaneous
MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
23.12.2025... ► Artikel lesen | |
| MARINOMED BIOTECH | 18,100 | 0,00 % | Marinomed-Aktie: Ist das eine ganz heiße Wette? | Wenn die Aktie eines Biotech-Unternehmens wie die der österreichischen Marinomed ein Kursdebakel erlebt und binnen fünf Jahren fast -90% an Wert verliert, dann ist das ein für diesen Sektor typisches... ► Artikel lesen | |
| ARGENX | 651,00 | -0,34 % | BERNSTEIN RESEARCH stuft Argenx auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Argenx nach Zahlen zum vierten Quartal 2025 mit einem Kursziel von 875 Euro auf "Outperform" belassen. Fortschritte... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,480 | -1,56 % | Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) | New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM-304 Anticipated in 2026 Updated Phase 1/2 Data and Next... ► Artikel lesen | |
| CHROME HOLDING | 0,630 | -18,16 % | 23andMe Research Institute; Troper Wojcicki Philanthropies, Lifebit: Lung Cancer Genetics Study Launches Open-Source Data Platform to Research Community | No-cost access available to qualified researchers via open-source federated data platformSAN FRANCISCO, Sept. 06, 2025. Launched in 2024, the Lung Cancer Genetics Study aims to enroll 10,000 individuals... ► Artikel lesen | |
| PHARVARIS | 23,000 | -4,96 % | Pharvaris N.V.: Pharvaris Outlines 2026 Strategic Priorities | Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026Preparation of NDA dossier of deucrictibant for on-demand treatment of... ► Artikel lesen |
Das Unternehmen BIOVERSYS AG kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 25,200 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOVERSYS AG finden Sie auf Wallstreet Online.